Clinical trials: Advanced Malignant Tumors
Advanced Cancer, Ovarian Cancer
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
- Conditions
- Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT03667716
- Testing
- COM701, COM701 with Opdivo (Nivolumab).
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Compugen Ltd
Solid Tumor Cancer, Lymphoma
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
SB-485232 will be administered as five daily intravenous (IV) infusions repeated every 28 days in adult subjects with advanced solid tumors or lymphomas.
- Trial name
- NCT00085904
- Testing
- SB-485232
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Mesothelioma, Mesotheliomas Pleural
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum
- Trial name
- NCT05451849
- Testing
- TC-510, Fludarabine, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- TCR2 Therapeutics
Advanced Solid Tumors
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Objectives:To evaluate the safety and tolerability of BAT8008 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.
- Trial name
- NCT05620017
- Testing
- BAT8008 for Injection
- Where
- 2 sites in China
- Volunteers
- 182 people
- Sponsor
- Bio-Thera Solutions
Glioblastoma
Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma
The purpose of this study: Determining the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), pharmacokinetics characteristic, and dosage regimen of phase II/III of Chlorogenic acid for injection in the advanced…
- Trial name
- NCT02728349
- Testing
- Chlorogenic acid
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
Advanced Solid Tumors
Safety and Efficacy of LCL161 in Patients With Solid Tumors
The study will evaluate the safety of increasing doses of oral LCL161 in patients with solid tumors. It is primarily designed to evaluate the side effects and find the maximum tolerated dose of LCL161.
- Trial name
- NCT01098838
- Testing
- LCL161
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Thoracic Tumors, Non-small Cell Lung Cancer
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors
The purpose of this study is to evaluate the safety, RP2D and PK/pharmacodynamic profile of ES101 monotherapy in patients with advanced NSCLC and to further evaluate the antitumor efficacy of ES101 in advanced malignant thoracic…
- Conditions
- Thoracic Tumors, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04841538
- Testing
- ES101
- Sponsor
- Elpiscience Biopharma, Ltd.
Any Solid Tumor or Lymphoma
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
The primary objective of this study is to determine the maximum tolerated dose (MTD) and to establish the recommended phase 2 dose of oral OSI-027 when administered via 3 schedules, namely, intermittent, weekly, and continuous in…
- Trial name
- NCT00698243
- Testing
- OSI-027
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 128 people
- Sponsor
- Astellas Pharma Inc
Advanced Solid Tumors
A Study of SC10914 in Patients With Advanced Solid Tumors
SC10914 is a potent selective PARP-1 and PARP-2 inhibitor. This study aims to determine the safety , tolerability , pharmacokinetic/pharmacodynamics profile of increasing doses of SC10914 when administered orally to patients with…
- Trial name
- NCT02940132
- Testing
- SC10914
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
PIK3CA Mutation, Solid Tumor, Adult
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
This is a Phase 1, first-in-human, open-label study designed to evaluate the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor…
- Conditions
- PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer
- Trial name
- NCT05759949
- Testing
- RLY-5836, Fulvestrant, Palbociclib
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Relay Therapeutics, Inc.
Carcinoma, Advanced Cancer
Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients
TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer cell lines.
- Trial name
- NCT02703298
- Testing
- TRX-818 capsules
- Where
- Taiwan
- Volunteers
- 19 people
- Sponsor
- TaiRx, Inc.
HER2-expressing Advanced Solid Tumors
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A1811 combined with other antitumor therapies in advanced solid tumors.
- Trial name
- NCT06015048
- Testing
- SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies
- Where
- 15 sites in China
- Volunteers
- 364 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
This study is designed to evaluate the safety, tolerability, PKharmacokinetic profile and treatment effect of pamiparib in Chinese participants with advanced high-grade ovarian cancer (including fallopian cancer or primary…
- Trial name
- NCT03333915
- Testing
- Pamiparib
- Where
- 6 sites in China
- Volunteers
- 128 people
- Sponsor
- BeiGene
Carcinoid, Neuroendocrine
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features
The primary purpose of the study is to determine if Seneca Valley Virus may be administered safely to patients with certain types of advanced cancer.
- Trial name
- NCT00314925
- Testing
- Seneca Valley Virus (biological agent)
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Neotropix
Cancer, Solid Tumor Cancer
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies.
- Conditions
- Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate
- Trial name
- NCT07424547
- Testing
- SYS6043
- Where
- 5 sites in United States
- Volunteers
- 386 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Solid Tumors
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive
- Trial name
- NCT02881138
- Testing
- RC48-ADC
- Where
- China
- Volunteers
- 24 people
- Sponsor
- RemeGen Co., Ltd.
Advanced Solid Tumors or Lymphomas
A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas
This is a phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JS019 as monotherapy in patients with advanced malignant solid tumors/lymphomas.
- Trial name
- NCT05374226
- Testing
- JS019
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Suzhou Kebo Ruijun Biotechnology Co., Ltd
Hepatocellular Carcinoma, Hepatoma
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
This study is an open-label, multi-center, phase 1, dose escalation study with a phase 2 expansion cohort to determine the safety, pharmacokinetics and preliminary anti-tumor activity of intravenous TKM-080301 in subjects with…
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Adult
- Trial name
- NCT02191878
- Testing
- TKM-080301
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 43 people
- Sponsor
- Arbutus Biopharma Corporation
Solid Tumor
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
This study is an open-label, multicenter, Phase I/IIa, dose escalation, safety, and pharmacokinetics (PK) study of BNT142 followed by expansion cohorts in patients with Claudin 6 (CLDN6)-positive advanced tumors.
- Trial name
- NCT05262530
- Testing
- BNT142
- Where
- 18 sites in United States, Singapore and 2 more
- Volunteers
- 73 people
- Sponsor
- BioNTech SE
Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
study evaluates EB-NK-301, an investigational off-the-shelf allogeneic CAR-NK cell product targeting TROP2, in adults with advanced or metastatic solid tumors that express TROP2 and have progressed after standard therapy.
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors
- Trial name
- SOLID-NK (NCT07589530)
- Testing
- EB-NK-301, Fludarabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.